Condition
Neoplastic Meningitis
Total Trials
6
Recruiting
0
Active
0
Completed
2
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
66.7%
4 terminated out of 6 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
150%
3 of 2 completed with results
Key Signals
3 with results33% success
Data Visualizations
Phase Distribution
6Total
Not Applicable (1)
P 1 (4)
P 2 (1)
Trial Status
Terminated4
Completed2
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT00924820Phase 1CompletedPrimary
A Pilot Study of Bevacizumab for Neoplastic Meningitis
NCT00512460Phase 1TerminatedPrimary
RTA 744 Injection in Patients With Leptomeningeal Disease
NCT00964743Not ApplicableTerminatedPrimary
Depocyt® With Sorafenib in Neoplastic Meningitis
NCT00523939Phase 2TerminatedPrimary
DepoCyt for Active Lymphomatous or Leukemic Meningitis
NCT00674674Phase 1CompletedPrimary
Phase 1 Intrathecal Topotecan for Neoplastic Meningitis
NCT00515788Phase 1TerminatedPrimary
DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis
Showing all 6 trials